Skip to main content
SpringerLink
Log in

Subcutaneous Administration of Immunoglobulins

What Are the Advantages?

  • Disease Management
  • Published:
Clinical Immunotherapeutics Aims and scope Submit manuscript

Summary

Immunoglobulin (IgG) therapy has hitherto mainly been given as intramuscular injections or intravenous infusions. However, due to disadvantages using these methods, we have developed a method for rapid subcutaneous infusion of IgG which is well tolerated (no virus transmission and no severe adverse reactions), improves the health-related quality of life, is highly appreciated by patients and leads to reduced costs for the healthcare sector and the patients. Altogether, more than 60 000 subcutaneous IgG infusions have now been given to patients with primary and secondary antibody deficiencies. Our experience suggests that this form of therapy constitutes the current treatment of choice both for the clinician and the patient.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Gardulf A, Hammarström L, Smith CIE. Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion. Lancet 1991; 338: 162–6

    Article  PubMed  CAS  Google Scholar 

  2. Gardulf A, Andersen V, Björkander J, et al. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet 1995; 345: 365–9

    Article  PubMed  CAS  Google Scholar 

  3. Gardulf A, Björvell H, Gustafson R, et al. The life situations of patients with primary antibody deficiency untreated or treated with subcutaneous gammaglobulin infusions. Clin Exp Immunol 1993; 92: 200–4

    Article  PubMed  CAS  Google Scholar 

  4. Gardulf A, Björvell H, Andersen V, et al. Lifelong treatment with gammaglobulin for patients with primary antibody deficiencies. The patients’ experiences of subcutaneous self-infusions and home therapy. J Adv Nurs 1995; 21: 917–27

    Article  PubMed  CAS  Google Scholar 

  5. Waniewski J, Gardulf A, Hammarström L. Bio-availability of gammaglobulin after subcutaneous infusions in patients with common variable immunodeficiency. J Clin Immunol 1994; 14: 90–7

    Article  PubMed  CAS  Google Scholar 

  6. Gardulf A, Möller G, Jonsson E. A comparison of the patient-borne costs of therapy with gamma globulin given at the hospital or at home. Int J Technol Assess Health Care 1995; 11: 345–53

    Article  PubMed  CAS  Google Scholar 

  7. Rosen FS, Wedgewood RJ, Eibl M, et al. Primary immunodeficiency diseases. Report of a WHO scientific group. Immunodefic Rev 1992; 3: 195–236

    Google Scholar 

  8. Bruton O. Agammaglobulinemia. Pediatrics 1952; 9: 722–8

    PubMed  CAS  Google Scholar 

  9. Brennan VM, Cochrane S, Fletcher C, et al. Surveillance of adverse reactions in patients self-infusing intravenous immunoglobulin at home. J Clin Immunol 1995; 15: 116–9

    Article  PubMed  CAS  Google Scholar 

  10. Yap PL, McOmish F, Webster ADB, et al. Hepatitis C virus transmission by intravenous immunoglobulin. J Hepatol 1994; 21: 455–60

    Article  PubMed  CAS  Google Scholar 

  11. Dalakas MC. High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology 1994; 44: 223–6

    Article  PubMed  CAS  Google Scholar 

  12. Tan E, Hajinazarin M, Bay W, et al. Acute renal failure resulting from intravenous immunoglobulin therapy. Arch Neurol 1993; 50: 136–9

    Article  Google Scholar 

  13. Casteels-van Daele M, Wijndaele L, Hunninck K, et al. Intravenous immune globulin and acute aseptic meningitis. N Engl JMed 1990; 323: 614–5

    CAS  Google Scholar 

  14. Berger M, Cupps T, Fauci A. Immunoglobulin replacement therapy by slow subcutaneous infusion. Ann Intern Med 1980; 93: 55–6

    PubMed  CAS  Google Scholar 

  15. van der Meer JWM, van Furth R, Roord JJ. Subcutaneous administration of gammaglobulin. In: Nydegger UE, ed. Immunotherapy: a guide to immunoglobulin prophylaxis and therapy. London: Academic Press, 1981: 133–42

    Google Scholar 

  16. Ugazio AG, Duse M, Re R, et al. Subcutaneous infusion of gammaglobulins in management of agammaglobulinaemia. Lancet 1982; I: 226

    Article  Google Scholar 

  17. Roord JJ, van der Meer JWM, Wietse K, et al. Home treatment in patients with antibody deficiency by slow subcutaneous infusion of gammaglobulin. Lancet 1982; I: 689–90

    Google Scholar 

  18. Berger M, Cupps TR, Fauci AS. High-dose immunoglobulin replacement by slow subcutaneous infusion during pregnancy. JAMA 1982; 247: 2824–5

    Article  PubMed  CAS  Google Scholar 

  19. Welch JM, Stiehm ER. Slow subcutaneous immunoglobulin therapy in a patient with reactions to intramuscular immunoglobulin. J Clin Immunol 1983; 3: 285–6

    Article  PubMed  CAS  Google Scholar 

  20. Ugazio AG, Duse M, Plebani A, et al. Subcutaneous infusion of gamma globulins in the management of agammaglobulinaemic patients. Birth Defects 1983; 19: 213–5

    PubMed  CAS  Google Scholar 

  21. Ugazio AG, Duse M, Plebani A, et al. Subcutaneous infusion of human standard globulin (HSG): clinical trial with two different dosages. In: Griscelli I, Vossen C, eds. Progress in immunodeficiency research and therapy I. Excerpta Medica International Congress Series. Amsterdam: Elsevier, 1984: 441–8

    Google Scholar 

  22. Bayston K, Leahy MF, McCreanor JD, et al. Subcutaneous gammaglobulin: effective management of hypogammaglobulinaemia. NZ Med J 1985; 652

    Google Scholar 

  23. Effersøe H, Anderson V. Subcutan infusion af IgG hos patienter med hypogammaglobulinaem [abstract in English]. Ugeskr Laeger 1985; 147: 3303–5

    PubMed  Google Scholar 

  24. Maródi L, Szabó I, Pálóczi K, et al. Subkutan gammaglobulin substitutuio X-hez kötött agammaglobulinaemiában. Orv Hetil 1986; 27: 1621–3

    Google Scholar 

  25. van der Meer JMW, de Windt GE, van den Broek PI, et al. Subcutaneous immunoglobulin substitution in hypogammaglobulinemia. In Krijnen HW, Strengers PEW, von Aken WG, eds. Immunoglobulins. Amsterdam: Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, 1988: 71–7

    Google Scholar 

  26. Remvig I, Andersen V, Hansen NE, et al. Prophylactic effect of self-administered pump-driven subcutaneous IgG infusion in patients with antibody deficiency: a triple-blind cross-over study comparing P-IgG levels of 3 g 1−1 versus 6 g 1−1. J Intern Med 1991; 229: 73–7

    Article  PubMed  CAS  Google Scholar 

  27. Wedgewood RJ. Intravenous immunoglobulin. Clin Immunol Immunopathol 1986; 40: 147–50

    Article  PubMed  CAS  Google Scholar 

  28. Chapel H, Brennan V, Delson E. Immunoglobulin replacement therapy by self-infusion at home. Clin Exp Immunol 1988; 73: 160–2

    PubMed  CAS  Google Scholar 

  29. Long AA, Denburg JA, Dent PB. Hypogammaglobulinemia: therapeutic rationale. Can Med Assoc J 1987; 137: 793–7

    CAS  Google Scholar 

  30. AIDS and the safety of blood and blood products: new WHO recommendations. WHO Chronicle 1986: 125–6

  31. Barandun S, Kistler P, Jeunet F, et al. Intravenous administration of gammaglobulin. Vox Sang 1962; 7: 157–74

    Article  PubMed  CAS  Google Scholar 

  32. Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. Lancet 1995; 345: 1312–3

    Article  PubMed  CAS  Google Scholar 

  33. Gardulf A. Rapid subcutaneous immunoglobulin replacement therapy in patients with primary antibody deficiency: aspects of effectiveness, safety, home therapy, quality of life and costs [dissertation]. ISBN 91-628-1403-6. Stockholm: Karolinska Institutet, 1994

    Google Scholar 

  34. Hammarström L, Gardulf A, Hammarström V, et al. Systemic and topical immunoglobulin treatment in immunocompromised patients. Immunol Rev 1994; 139: 43–70

    Article  PubMed  Google Scholar 

  35. Hammarström L, Samuelsson J, Grimfors G. Subcutaneous gammaglobulin for patients with secondary hypogamma-globulinaemia. Lancet 1995; 345: 382–3

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Clinical Immunology, Department of Immunology, Microbiology, Pathology and Infectious Diseases, The Karolinska Institute at Huddinge University Hospital, Stockholm, Sweden

    Ann Gardulf & Lennart Hammarström

Authors
  1. Ann Gardulf
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lennart Hammarström
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gardulf, A., Hammarström, L. Subcutaneous Administration of Immunoglobulins. Clin. Immunother. 6, 108–116 (1996). https://doi.org/10.1007/BF03259507

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03259507

Keywords

Search

Navigation